These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 30479195)

  • 1. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
    Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
    Leung JH; Lang HC; Wang SY; Lo HF; Chan AL
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):489-496. PubMed ID: 34241562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
    Guy H; Walder L; Fisher M
    Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
    Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
    J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
    Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
    [No Abstract]   [Full Text] [Related]  

  • 13. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
    Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by
    Cheng LJ; Wong G; Chay WY; Ngeow J; Tan Y; Soon SS; Aziz MIA; Pearce F; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):441-448. PubMed ID: 33593205
    [No Abstract]   [Full Text] [Related]  

  • 18. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
    Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.